Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 496 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 0.9% Normal Saline (0.9% Sodium Chloride) injection Clear all
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Lipomas Treated With Subcutaneous Injections of Cooled or Warmed Sodium Chloride

NCT06820164
View directory record Official record
Conditions
Lipoma
Interventions
Cooled Sodium Chloride Injection, Warmed Sodium Chloride Injection
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 15, 2026, 10:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of Transversus Abdominis Plane Block Versus Local Injection of Pain Medication

NCT02314104
View directory record Official record
Conditions
Pain, Postoperative
Interventions
ropivacaine
Drug
Lead sponsor
Liberman, Eric, D.O.
Individual
Eligibility
18 Years and older · Female only
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Livingston, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 15, 2026, 10:36 AM EDT
Terminated Phase 2 Interventional Results available

Phase IIb Study of IFN-K in Systemic Lupus Erythematosus

NCT02665364
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
IFNα-Kinoid, Placebo, ISA 51 VG
Biological · Other
Lead sponsor
Neovacs
Industry
Eligibility
18 Years to 65 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
13
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 15, 2026, 10:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Numeta G16%E

NCT06842134
View directory record Official record
Conditions
Parenteral Nutrition
Interventions
Numeta G16%E, Sodium Glycerophosphate Injection
Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 15, 2026, 10:36 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults

NCT00442169
View directory record Official record
Conditions
West Nile Fever
Interventions
ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose, 0.9% Saline solution, 0.9 % NaCl solution
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
5
States / cities
Phoenix, Arizona • Idaho Falls, Idaho • Lenexa, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 15, 2026, 10:36 AM EDT
Withdrawn Phase 1 Interventional

A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure

NCT04574869
View directory record Official record
Conditions
Acute Lung Injury, ALI, COVID-19
Interventions
RLS-0071 10 mg/kg, RLS-0071 40 mg/kg, Placebo
Drug
Lead sponsor
ReAlta Life Sciences, Inc.
Industry
Eligibility
18 Years to 69 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 15, 2026, 10:36 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

NCT04516746
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
AZD1222, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
32,450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
78
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 66 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 15, 2026, 10:36 AM EDT
Completed Phase 2 Interventional Results available

IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3

NCT03401073
View directory record Official record
Conditions
Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy
Interventions
Intravenous immunoglobulin, 0.9% Sodium Chloride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 15, 2026, 10:36 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

NCT06897202
View directory record Official record
Conditions
Obesity in Diabetes, Type 2 Diabetes Mellitus (T2DM)
Interventions
MET097 Injection, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
29
States / cities
Bessemer, Alabama • Chula Vista, California • Glendale, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 15, 2026, 10:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

NCT02963831
View directory record Official record
Conditions
Colorectal Cancer, Ovarian Cancer, Appendiceal Cancer
Interventions
ONCOS-102, Durvalumab, Cyclophosphamide
Biological · Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
San Diego, California • Miami, Florida • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 15, 2026, 10:36 AM EDT
Completed Not applicable Interventional Results available

Can Single-Injection Adductor Canal Blocks Improve PostOp Pain Relief in Patients Undergoing Total Knee Arthroplasty?

NCT02276495
View directory record Official record
Conditions
Pain Management
Interventions
ACB Control - 20 ml saline injection for ACB, ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block, Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
Other · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 15, 2026, 10:36 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy

NCT02762929
View directory record Official record
Conditions
Postoperative Pain, Bunions
Interventions
HTX-011A, Saline Placebo, HTX-011B, HTX-002, Bupivacaine HCl, HTX-009
Drug · Biological
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Anaheim, California • Bakersfield, California • Pasadena, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 15, 2026, 10:36 AM EDT
Completed Phase 2 Interventional Results available

Micronized dHACM vs. Saline in the Treatment of Osteoarthritis of the Knee

NCT03485157
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Micronized dHACM, Saline
Biological · Drug
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
17
States / cities
Birmingham, Alabama • Tempe, Arizona • La Mesa, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 15, 2026, 10:36 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effect of GLP-1 on Postprandial Lipid Metabolism

NCT01760772
View directory record Official record
Conditions
Heart Disease
Interventions
Exendin-9, GLP-1, saline
Drug · Other
Lead sponsor
David Dalessio
Other
Eligibility
40 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 15, 2026, 10:36 AM EDT
Completed Phase 2 Interventional

Evaluating New Formulation of Therapeutic HSV-2 Vaccine

NCT02515175
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
Matrix-M2, GEN-003, Placebo
Biological · Drug
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 15, 2026, 10:36 AM EDT
Completed Phase 2 Interventional Results available

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)

NCT02597127
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia, Diabetes
Interventions
ALN-PCSSC, Normal Saline
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 99 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 17, 2019 · Synced Oct 15, 2026, 10:36 AM EDT
Completed Phase 1 Interventional

Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients

NCT04555486
View directory record Official record
Conditions
Primary Hyperoxaluria Type 3
Interventions
DCR-PHXC, Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
6 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 15, 2026, 10:36 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older

NCT04798027
View directory record Official record
Conditions
COVID-19
Interventions
SARS-CoV-2 mRNA vaccine formulation 1, SARS-CoV-2 mRNA vaccine formulation 2, SARS-CoV-2 mRNA vaccine formulation 3, Placebo (0.9% normal saline)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
12
States / cities
Rolling Hills Estates, California • Hollywood, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 15, 2026, 10:36 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

NCT04470427
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30,415 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
100
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 15, 2026, 10:36 AM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 15, 2026, 10:36 AM EDT
Completed Phase 1Phase 2 Interventional

Joint Injections for Osteoarthritic Knee Pain

NCT00085722
View directory record Official record
Conditions
Osteoarthritis
Interventions
Dextrose Prolotherapy, Saline Prolotherapy, At-home physical therapy exercise group
Procedure · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
40 Years to 70 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 15, 2026, 10:36 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Comparing Intra-articular Corticosteroid to Intra-articular Ketorolac Knee Injections

NCT02612272
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Ketorolac, Betamethasone
Drug
Lead sponsor
St. Luke's Hospital, Pennsylvania
Other
Eligibility
18 Years and older · Male only
Enrollment
448 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2016 · Synced Oct 15, 2026, 10:36 AM EDT
Completed Phase 4 Interventional Results available

Sternal Block With Liposomal Bupivacaine vs. Saline Prior to Incision in Cardiac Surgery

NCT04333095
View directory record Official record
Conditions
Cardiovascular Surgery, Pain, Postoperative, Block
Interventions
Liposomal bupivacaine, Normal Saline Flush, 0.9% Injectable Solution_#1
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 15, 2026, 10:36 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Bacteriostatic Saline to Buffered Lidocaine for Ultrasound Guided Hip Joint Injection Local Anesthesia

NCT02209272
View directory record Official record
Conditions
Hip Pain
Interventions
bacteriostatic saline, buffered lidocaine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Oct 15, 2026, 10:36 AM EDT